Compare Cigna Corp (CI) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs Lemonade Inc — how do they compare? Cigna Corp trades at $272.72 (market cap $73.56B), while Lemonade Inc trades at $52.87 (market cap $4.08B). The key difference: Cigna Corp is far larger — about 18× Lemonade Inc's market cap, and Cigna Corp pays a 2.24% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals.
| CI | LMND | |
|---|---|---|
Market Cap | $73.56B | $4.08B |
Sector | Health | Financials |
52-Week High | $311.00 | $96.57 |
52-Week Low | $244.41 | $47.38 |
Enterprise Value | $98.27B | $3.94B |
Dividend Yield | 2.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $282.49, up 2.63% with strong earnings beats in recent quarters. The stock shows bearish technical signals but benefits from low valuation ratios like a P/E of 11.68 and P/S of 0.27. Recent Q2 2026 results exceeded expectations, with EPS of $7.78 beating estimates, and the company raised its full-year guidance to at least $30.45 adjusted EPS, reflecting robust growth in health services and insurance segments.
The outlook is positive due to consistent earnings outperformance and raised guidance, though technical weakness and competitive pressures pose risks. Analyst consensus is strongly bullish with a $338.90 price target, indicating ~20% upside potential from current levels, supported by dividend payments and institutional accumulation.
Lemonade (LMND) trades at $52.94, up 2.08% today, with a bearish technical signal from moving averages despite recent earnings beats. Revenue growth is strong at 79% year-over-year in Q2 2026, but profitability remains elusive with a net income margin of -14.19% in 2025. The company targets positive adjusted EBITDA by Q4 2026, supported by expanding insurance offerings in states like Nebraska and Maine.
The outlook is mixed: accelerating premium growth and path to profitability offer upside, but high valuation (P/S of 4.11) and persistent losses pose risks. Analyst consensus is evenly split, with a $58 price target suggesting modest upside from current levels, though technical resistance near $54 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
